Ectodomain structures of the CGRP and AM receptors

Current Protein and Peptide Science

Volumn 14, Issue 5, 2013, Pages 375-385

  Kusano, Seisuke ^a   Yokoyama, Shigeyuki ^a  

^a RIKEN   (Japan)

Author keywords

Adrenomedullin; Antagonist; Calcitonin gene related peptide; Calcitonin receptor like receptor; Crystal structure; Migraine; Neovascularization; Receptor activity modifying protein

Indexed keywords

ADRENOMEDULLIN RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN RECEPTOR LIKE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; DOPAMINE RECEPTOR; DUAL SPECIFICITY PHOSPHATASE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; HISTAMINE RECEPTOR; LIGAND; MUSCARINIC RECEPTOR; OLCEGEPANT; OPIATE RECEPTOR; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; TELCAGEPANT;

ARTICLE; CHEMICAL PHENOMENA; COMPUTER INTERFACE; CRYSTAL STRUCTURE; DNA HELIX; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYDROGEN BOND; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SEQUENCE ALIGNMENT;

ADRENOMEDULLIN; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; RECEPTORS, ADRENOMEDULLIN; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 84882724902     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990054     Document Type: Article

References (74)

1. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G proteincoupled receptors and significance for drug discovery. Nat. Rev. Drug Discov., 2008, 7(4), 339-357.
2. Woehler A, Ponimaskin E. G. G protein--mediated signaling: same receptor, multiple effectors. Curr.Mol.Pharmacol.,2009, 2 (3):237-248.
3. Jalink K, Moolenaar W. H. G protein-coupled receptors: the inside story. Bioessays 2010, 32 (1),13-16.
4. Whalen E. J., Rajagopal S, Lefkowitz R. J. Therapeutic potential of beta-arrestin-and G protein-biased agonists. Trends Mol. Med.,2011, 17 (3):126-139.
5. Fredriksson R, Lagerstrom M. C.;, Lundin L.G.; Schioth H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 2003,63 (6),1256-1272.
6. Fredriksson R, Lagerstrom M.C.; Schioth, H. B. Expansion of the superfamily of G-protein-coupled receptors in chordates. Ann. N. Y.Acad. Sci., 2005,1040:89-94.
7. Millar, R.P.; Newton, C. L. The year in G protein-coupled receptor research. Mol. Endocrinol. 2010,24 (1):261-274.
8. Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of G-protein-coupled receptors. Nature, 2009, 459 (7245), 356-363.
9. Katritch, V.; Cherezov, V.; Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 2012,33 (1):17-27.
10. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D.M.; Kobilka, T. S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R., Fischetti R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic G-proteincoupled receptor. Nature, 2007;450 (7168):383-387.
11. Cherezov, V.; Rosenbaum, D. M.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007,318 (5854),1258-1265.
12. Jaakola, V. P.; Griffith, M.T; Hanson, M. A; Cherezov, V.; Chien, E. Y.; Lane, J. R; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322 (5905),1211-1217.
13. Wu, B.; Chien, E. Y.; Mol, C. D; Fenalti, G.; Liu, W.; Katritch, V; Abagyan, R.; Brooun, A; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science, 2010,330 (6007),1066-1071.
14. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M.A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 2010,330 (6007):1091-1095.
15. Shimamura, T.; Shiroishi, M.; Weyand, S.; Tsujimoto, H.; Winter, G.; Katritch, V.; Abagyan, R.; Cherezov, V.; Liu, W.; Han, G. W.; Kobayashi, T.; Stevens, R. C.; Iwata, S. Structure of the human histamine H1 receptor complex with doxepin. Nature, 2011,475 (7354):65-70.
16. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W.I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature, 2012,482 (7386),547-551.
17. Hanson, M. A.; Roth, C. B.; Jo, E.; Griffith, M. T.; Scott, F. L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, S. M.; Schuerer, S. C.; Sanna, M. G.; Han, G. W.; Kuhn, P.; Rosen, H.; Stevens, R. C. Crystal structure of a lipid G protein-coupled receptor. Science, 2012, 335 (6070),851-855.
18. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic. Nature, 2012,485 (7398),327-332.
19. Thompson A. A.; Liu, W.; Chun E.; Katritch, V.; Wu, H.; Vardy, E.; Huang, X.P.; Trapella, C.; Guerrini, R.; Calo, G.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature, 2012,485 (7398),395-399.
20. Vaudry, D.; Falluel-Morel, A.; Bourgault, S.; Basille, M.; Burel, D.; Wurtz, O.; Fournier, A.; Chow, B. K.; Hashimoto, H.; Galas, L.; Vaudry, H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev., 2009,61 (3),283-357.
21. Parthier, C.; Reedtz-Runge, S.; Rudolph, R.; Stubbs M. T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci., 2009,34 (6),303-310.
22. Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug Discov., 2009,8 (5),369-385.
23. Watkins, H. A.; Au, M.; Hay, D. L. The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development. Drug Discov. Today, 2012,17 (17-18),1006-1014.
24. Parthier, C.; Kleinschmidt, M.; Neumann, P.; Rudolph, R.; Manhart, S.; Schlenzig, D.; Fanghanel, J.; Rahfeld, J. U.; Demuth, H. U.; Stubbs, M. T. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc. Natl. Acad. Sci. U. S. A., 2007,104 (35),13942-13947.
25. Sun, C.; Song, D.; Davis-Taber R. A.; Barrett, L. W.; Scott, V. E.; Richardson, P. L.; Pereda-Lopez A.; Uchic, M. E.; Solomon, L. R.; Lake, M. R.; Walter, K. A.; Hajduk, P. J.; Olejniczak, E. T. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc. Natl. Acad. Sci. U. S. A., 2007,104 (19),7875-80.
26. Pioszak, A. A.; Xu, H. E. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc. Natl. Acad. Sci. U. S. A., 2008,105 (13):5034-5039.
27. Pioszak, A. A.; Parker, N. R.; Suino-Powell, K.; Xu, H. E. Molecular recognition of corticotropin-releasing factor by its G-proteincoupled receptor CRFR1. J. Biol. Chem., 2008,283 (47),32900-32912.
28. Pal, K.; Swaminathan, K.; Xu, H. E.; Pioszak, A. A. Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor. J. Biol. Chem., 2010,285 (51):40351-40361.
29. Runge, S.; Thogersen, H.; Madsen, K.; Lau, J.; Rudolph, R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem., 2008.
30. Koth, C. M.; Murray, J. M.; Mukund, S.; Madjidi, A.; Minn, A.; Clarke, H. J.; Wong, T.; Chiang, V.; Luis, E.; Estevez, A.; Rondon, J.; Zhang, Y.; Hotzel, I.; Allan. B. B. Molecular basis for negative regulation of the glucagon receptor. Proc. Natl. Acad. Sci. U. S. A., 2012,109 (36),14393-14398.
31. Couvineau, A.; Laburthe, M. The family B1 GPCR: structural aspects and interaction with accessory proteins. Curr. Drug. Targets, 2012,13 (1),103-115.
32. Barwell, J.; Gingell, J. J.; Watkins, H. A.; Archbold, J. K.; Poyner, D. R.; Hay, D. L. Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs? Br. J. Pharmacol., 2012,166 (1),51-65.
33. McLatchie, L. M.; Fraser, N. J.; Main, M. J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M. G.; Foord, S. M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptorlike receptor. Nature,1998,393 (6683),333-339.
34. Bomberger, J. M.;. Parameswaran, N.; Spielman, W. S. Regulation of GPCR trafficking by RAMPs. Adv. Exp. Med. Biol., 2012,744,25-37.
35. Sexton, P. M.; Albiston, A.; Morfis, M.; Tilakaratne, N. Receptor activity modifying proteins. Cell Signal, 2001,13 (2),73-83.
36. Born, W.; Fischer, J. A.; Muff, R. Receptors for calcitonin generelated peptide, adrenomedullin, and amylin: the contributions of novel receptor-activity-modifying proteins. Receptors Channels, 2002,8 (3-4),201-209.
37. Christopoulos, G.; Perry, K. J.; Morfis, M.; Tilakaratne, N.; Gao, Y.; Fraser, N. J.; Main, M. J.; Foord, S. M.; Sexton, P. M. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol., 1999,56 (1),235-242.
38. Morfis, M.; Tilakaratne, N.; Furness, S. G.; Christopoulos, G.; Werry, T. D.; Christopoulos, A.; Sexton, P. M. Receptor activitymodifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology, 2008,149 (11),5423-5431.
39. Qi, T.; Christopoulos, G.; Bailey, R. J.; Christopoulos A.; Sexton, P. M.; Hay, D. L. Identification of N-terminal receptor activity modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol. Pharmacol., 2008,74 (4),1059-1071.
40. Christopoulos, A.; Christopoulos, G.; Morfis, M.; Udawela, M.; Laburthe, M.; Couvineau, A.; Kuwasako, K.; Tilakaratne, N.; Sexton, P. M. Novel receptor partners and function of receptor activitymodifying proteins. J. Biol. Chem.,2003,278 (5),3293-3297.
41. Parameswaran, N.; Spielman, W. S. RAMPs: The past, present and future. Trends Biochem.Sci., 2006,31 (11),631-638.
42. Wootten, D.; Lindmark, H.; Kadmiel, M.; Willcockson, H.; Caron, K. M.; Barwell, J.; Drmota, T.; Poyner, D. R. Receptor Activity Modifying Proteins (RAMPs) Interact with the VPAC(2) Receptor and CRF(1) Receptors and modulate their function. Br. J. Pharmacol., 2012.
43. Bouschet, T.; Martin, S.; Henley, J. M. Receptor-activitymodifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J. Cell Sci. 2005,118 (Pt 20),4709-4720.
44. Kunz, T. H.; Mueller-Steiner, S.; Schwerdtfeger, K.; Kleinert, P.; Troxler, H.; Kelm, J. M.; Ittner, L. M.; Fischer, J. A.; Born, W. Interaction of receptor-activity-modifying protein1 with tubulin. Biochim. Biophys. Acta., 2007,1770 (8),1145-1150.
45. Archbold, J. K.; Flanagan, J. U.; Watkins, H. A.; Gingell, J. J.; Hay, D. L. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol. Sci., 2011,32 (10),591-600.
46. Sexton, P. M.; Poyner, D. R.; Simms, J.; Christopoulos, A.; Hay, D. L. RAMPs as drug targets. Adv. Exp. Med. Biol., 2012,744,61-74.
47. ter Haar, E.; Koth, C. M.; Abdul-Manan, N.; Swenson, L.; Coll, J. T.; Lippke, J. A.; Lepre, C. A.; Garcia-Guzman, M.; Moore, J. M. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure, 2010,18 (9),1083-1093.
48. Kusano, S.; Kukimoto-Niino, M.; Hino, N.; Ohsawa, N.; Okuda, K.; Sakamoto, K.; Shirouzu, M.; Shindo, T.; Yokoyama, S. Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding. Protein Sci.,2012,21 (2),199-210.
49. Kusano, S.; Kukimoto-Niino, M.; Akasaka, R.; Toyama, M.; Terada, T.; Shirouzu, M.; Shindo, T.; Yokoyama, S. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein. Sci.,2008,17 (11),1907-1914.
50. Barwell, J.; Miller, P. S.; Donnelly, D.; Poyner, D. R. Mapping interaction sites within the N-terminus of the calcitonin generelated peptide receptor; the role of residues 23-60 of the calcitonin receptor-like receptor. Peptides,2010, 31 (1),170-176.
51. Kuwasako, K.; Kitamura, K.; Nagoshi, Y.; Cao, Y. N.; Eto, T. Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J. Biol. Chem., 2003,278 (25),22623-22630.
52. Simms, J.; Hay, D. L.; Wheatley, M.; Poyner, D. R. Characterization of the structure of RAMP1 by mutagenesis and molecular modeling. Biophys. J., 2006,91 (2),662-669.
53. Simms, J.; Hay, D. L.; Bailey, R. J.; Konycheva, G.; Bailey, G.; Wheatley M.; Poyner, D. R. Structure-function analysis of RAMP1 by alanine mutagenesis. Biochemistry, 2009,48 (1),198-205.
54. Kuwasako, K.; Kitamura, K.; Uemura, T.; Nagoshi, Y.; Kato, J.; Eto, T. The function of extracellular cysteines in the human adrenomedullin receptor. Hypertens. Res., 2003,26,Suppl,S25-S31.
55. Ittner, L. M.; Koller, D.; Muff, R.; Fischer, J. A.; Born, W. The Nterminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry, 2005,44 (15),5749-5754.
56. Flahaut, M.; Rossier, B. C.; Firsov, D. Respective roles of calcitonin receptor-like receptor (CRLR) and receptor activitymodifying proteins (RAMP) in cell surface expression of CRLR/RAMP heterodimeric receptors. J. Biol. Chem.,2002, 277 (17),14731-14737.
57. Kamitani, S.; Sakata, T. Glycosylation of human CRLR at Asn123 is required for ligand binding and signaling. Biochim. Biophys. Acta., 2001,1539 (1-2),131-139.
58. Kuwasako, K.; Kitamura, K.; Nagata, S.; Kato, J. Functions of the extracellular histidine residues of receptor activity-modifying proteins vary within adrenomedullin receptors. Biochem. Biophys. Res. Commun., 2008,377 (1),109-113.
59. Doods, H.; Hallermayer, G.; Wu, D.; Entzeroth, M.; Rudolf, K.; Engel, W.; Eberlein, W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol., 2000,129 (3),420-423.
60. Doods, H.; Arndt, K.; Rudolf, K.; Just, S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol. Sci., 2007, 28 (11),580-587.
61. Ho, T. W.; Ferrari, M. D.; Dodick, D. W.; Galet, V.; Kost, J.; Fan, X.; Leibensperger, H.; Froman, S.; Assaid, C.; Lines, C.; Koppen, H.; Winner, P. K. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet,2008, 372 (9656):2115-2123.
62. Miller, P. S.; Barwell, J.; Poyner, D. R.; Wigglesworth, M. J.; Garland, S. L.; Donnelly, D. Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochem,. Biophys. Res. Commun.,2010, 391 (1),437-442.
63. Koth, C. M.; Abdul-Manan, N.; Lepre, C. A.; Connolly, P. J.; Yoo, S.; Mohanty, A. K.; Lippke, J. A.; Zwahlen, J.; Coll, J. T.; Doran, J. D.; Garcia-Guzman, M.; Moore, J. M. Refolding and characterization of a soluble ectodomain complex of the calcitonin generelated peptide receptor. Biochemistry, 2010,49 (9),1862-1872.
64. Moore, E. L.; Gingell, J. J.; Kane, S. A.; Hay, D. L.; Salvatore, C. A. Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. Biochem. Biophys. Res. Commun., 2010, 394 (1),141-145.
65. Hoare, S. R. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug. Discov. Today, 2005, 10 (6),417-427.
66. Hoare, S. R. Allosteric modulators of class B G-protein-coupled receptors. Curr. Neuropharmacol, 2007,5 (3),168-179.
67. Chiba, T.; Yamaguchi, A.; Yamatani, T.; Nakamura, A.; Morishita, T.; Inui, T.; Fukase, M.; Noda, T.; Fujita, T. Calcitonin generelated peptide receptor antagonist human CGRP-(8-37). Am. J. Physiol., 1989,256 (2 Pt 1),E331-E335.
68. Maggi, C. A.; Chiba, T.; Giuliani, S. Human alpha-calcitonin generelated peptide-(8-37) as an antagonist of exogenous and endogenous calcitonin gene-related peptide. Eur. J. Pharmacol., 1991,192 (1),85-88.
69. Andreotti, G.; Vitale, R. M.; Avidan-Shpalter, C.; Amodeo, P.; Gazit, E.; Motta, A. Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue. J. Biol. Chem., 2011,286 (4),2707-2718.
70. Perez-Castells, J.; Martin-Santamaria, S.; Nieto, L.; Ramos, A.; Martinez, A.; Pascual-Teresa, B.; Jimenez-Barbero, J. Structure of micelle-bound adrenomedullin: a first step toward the analysis of its interactions with receptors and small molecules. Biopolymers, 2012,97 (1),45-53.
71. Barwell, J.; Conner, A.; Poyner, D. R. Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function. Biochim. Biophys. Acta., 2011, 1813 (10),1906-1916.
72. Barwell, J.; Woolley, M. J.; Wheatley, M.; Conner, A. C.; Poyner, D. R. The role of the extracellular loops of the CGRP receptor, a family B GPCR. Biochem. Soc. Trans., 2012,40 (2),433-437.
73. Kuwasako, K.; Hay, D. L.; Nagata, S.; Hikosaka, T.; Kitamura, K.; Kato, J. The third extracellular loop of the human calcitonin receptor-like receptor is crucial for the activation of adrenomedullin signalling. Br. J. Pharmacol., 2012,166 (1),137-150.
74. Qi, T.; Hay, D. L. Structure-function relationships of the Nterminus of receptor activity-modifying proteins. Br.J. Pharmacol., 2010,159 (5),1059-1068.